Latest Ratios: P/E Ratio -0.9x · EV/EBITDA N/A · ROE 5.3%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $4M | $1M | $993134 | $1M | $6M | $3M | $1M | $714328 | $1M | $3M |
| Enterprise Value | $15M | $16M | $32M | $30M | $-1681782 | $-70901717 | $1M | $3M | $395209 | $1M | $2M |
| P/E Ratio → | -0.93 | — | 0.04 | — | — | — | — | — | — | — | — |
| P/S Ratio | 39.71 | 62.55 | 0.46 | 0.41 | 3.78 | 12.71 | — | — | — | — | — |
| P/B Ratio | 0.16 | 0.20 | — | — | 0.13 | 0.08 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 228.89 | 10.70 | 12.27 | -4.46 | -141.80 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 1.13 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -354.9% | -354.9% | -101.6% | -161.8% | -858.6% | -17.0% | — | — | — | — | — |
| Operating Margin | -30712.7% | -30712.7% | -1485.4% | -2805.7% | -24161.0% | -10878.6% | — | — | — | — | — |
| Net Profit Margin | 564.8% | 564.8% | 1328.6% | -2617.3% | -23602.9% | -10069.4% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.3% | 5.3% | — | — | -197.0% | -127.5% | — | — | — | — | -3589.5% |
| ROA | 1.2% | 1.2% | 124.8% | -147.4% | -126.3% | -94.3% | -253.7% | -202.5% | -354.5% | -758.5% | -542.2% |
| ROIC | -56.6% | -56.6% | -232.4% | -800.3% | -1368.1% | — | — | — | — | — | — |
| ROCE | -227.3% | -227.3% | — | — | -197.6% | -137.8% | — | — | — | — | -3589.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.60 | 0.60 | — | — | 3.35 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.53 | — | — | -0.28 | -0.97 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1038.38 | -1038.38 | 632.71 | -133.57 | -79.59 | — | -440.58 | -510.77 | -6.34 | -12.14 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.06 | 0.45 | 1.07 | 10.93 | 0.94 | 0.55 | 0.77 | 0.64 | 0.62 |
| Quick Ratio | 0.16 | 0.16 | 0.05 | 0.44 | 1.06 | 10.86 | 0.89 | 0.55 | 0.77 | 0.64 | 0.62 |
| Cash Ratio | 0.10 | 0.10 | 0.03 | 0.36 | 1.04 | 10.49 | 0.87 | 0.52 | 0.75 | 0.60 | 0.49 |
| Asset Turnover | — | 0.00 | 0.10 | 0.07 | 0.01 | 0.01 | — | — | — | — | — |
| Inventory Turnover | 1.35 | 1.35 | 22.70 | 11.91 | 13.85 | 1.11 | — | — | — | — | — |
| Days Sales Outstanding | — | 77.11 | 2.19 | 9.08 | 16.46 | 146.00 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 1.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 2371.8% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 25.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 25.7% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $670466 | $2M | $241052 | $197947 | $172257 | $105405 | $67105 | $49503 | $29991 | $28827 |
Immediate insolvency and dilution
According to current market data, PAVM trades at a price-to-sales multiple of 37.67, a figure that appears disconnected from the company's near-zero revenue base and suggests investors are pricing the equity as a speculative option on potential intellectual property liquidation rather than a functioning business entity.
The elevated P/S ratio is a mathematical artifact of the revenue collapse rather than a signal of growth expectations. Given the negative P/E and lack of meaningful EBITDA, traditional valuation multiples fail to capture the existential risk, suggesting the market is assigning value primarily to the remaining patent portfolio.
As reported in financial statements, the company's ROIC has remained consistently negative over the last ten quarters, reaching -173.0% in 2026Q1, which indicates that every dollar of invested capital is currently destroying value rather than generating any form of sustainable economic return for shareholders.
The persistent negative returns on capital highlight a fundamental inability to deploy resources efficiently within the medical device incubator model. This trend suggests that the company's historical capital allocation strategy has failed to achieve the necessary scale to offset the high fixed costs of clinical development.
Based on the provided quarterly data, the company's asset turnover ratio has stagnated at 0.52 in 2026Q1, reflecting a severe inability to convert the firm's asset base into meaningful revenue, a trend that has persisted throughout the observed period as commercialization efforts have repeatedly failed to gain traction.
The lack of asset turnover indicates that the company's infrastructure, including its laboratory and manufacturing capabilities, remains largely underutilized. This inefficiency exacerbates the cash burn, as the firm continues to maintain a cost structure that is not supported by any corresponding level of operational throughput.
According to recent SEC filings, the company's current ratio has fluctuated significantly, yet the absolute cash position of $1.538 million as of 2025Q4 leaves the firm with a dangerously thin margin of safety against its ongoing operating losses and high fixed-cost obligations in the coming quarters.
The reliance on external financing to maintain operations is evident, as the current liquidity position is insufficient to support the company's historical burn rate. Investors should monitor the potential for immediate dilutive equity raises, as the current balance sheet lacks the resilience to withstand further operational delays.
Based on reported figures, the price-to-book ratio of 0.15 is the most commonly misapplied metric for this business model, as it erroneously suggests the stock is undervalued relative to its assets without accounting for the high probability of significant impairment to those assets in a liquidation scenario.
Using P/B to justify an investment in a distressed medical technology firm ignores the fact that the company's assets are largely intangible and highly specific to failed commercial products. A more appropriate focus would be the cash-burn-to-liquidity ratio, which provides a clearer picture of the firm's remaining runway.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PAVM stock.
PAVmed Inc.'s current P/E ratio is -0.9x. The historical average is 0.0x.
PAVmed Inc.'s return on equity (ROE) is 5.3%. The historical average is -127.4%.
Based on historical data, PAVmed Inc. is trading at a P/E of -0.9x. Compare with industry peers and growth rates for a complete picture.
PAVmed Inc. has -354.9% gross margin and -30712.7% operating margin.